Comments
Loading...

Beam Therapeutics

BEAMNASDAQ
Logo brought to you by Benzinga Data
$25.65
-0.39-1.50%
At Close: -
$26.00
0.351.36%
After Hours: 5:29 PM EDT
15 minutes delayed
Consensus Rating1
Outperform
Highest Price Target1
$130.00
Lowest Price Target1
$27.00
Consensus Price Target1
$60.65

Beam Therapeutics (NASDAQ:BEAM) Stock, Analyst Ratings, Price Targets, Forecasts

Beam Therapeutics Inc has a consensus price target of $60.65 based on the ratings of 18 analysts. The high is $130 issued by Guggenheim on January 5, 2022. The low is $27 issued by RBC Capital on September 19, 2024. The 3 most-recent analyst ratings were released by RBC Capital, Stifel, and HC Wainwright & Co. on September 19, 2024, September 11, 2024, and August 22, 2024, respectively. With an average price target of $58.67 between RBC Capital, Stifel, and HC Wainwright & Co., there's an implied 125.64% upside for Beam Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
May
0
0
0
0
Jul
1
1
Aug
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Stifel
HC Wainwright & Co.
JP Morgan
Barclays

1calculated from analyst ratings

Analyst Ratings for Beam Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Beam Therapeutics (BEAM) stock?

A

The latest price target for Beam Therapeutics (NASDAQ:BEAM) was reported by RBC Capital on September 19, 2024. The analyst firm set a price target for $27.00 expecting BEAM to rise to within 12 months (a possible 3.85% upside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Beam Therapeutics (BEAM)?

A

The latest analyst rating for Beam Therapeutics (NASDAQ:BEAM) was provided by RBC Capital, and Beam Therapeutics reiterated their sector perform rating.

Q

When was the last upgrade for Beam Therapeutics (BEAM)?

A

The last upgrade for Beam Therapeutics Inc happened on January 29, 2024 when JP Morgan raised their price target to $40. JP Morgan previously had a neutral for Beam Therapeutics Inc.

Q

When was the last downgrade for Beam Therapeutics (BEAM)?

A

The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.

Q

Is the Analyst Rating Beam Therapeutics (BEAM) correct?

A

While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a reiterated with a price target of $27.00 to $27.00. The current price Beam Therapeutics (BEAM) is trading at is $26.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch